GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (STU:EZ1) » Definitions » Debt-to-Asset

Enzon Pharmaceuticals (STU:EZ1) Debt-to-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Enzon Pharmaceuticals Debt-to-Asset?

Enzon Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Enzon Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Enzon Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €43.08 Mil. Enzon Pharmaceuticals's debt to asset for the quarter that ended in Mar. 2024 was 0.00.


Enzon Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Enzon Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals Debt-to-Asset Chart

Enzon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enzon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enzon Pharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, Enzon Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzon Pharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Enzon Pharmaceuticals's Debt-to-Asset falls into.



Enzon Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Enzon Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Enzon Pharmaceuticals's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzon Pharmaceuticals  (STU:EZ1) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Enzon Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzon Pharmaceuticals (STU:EZ1) Business Description

Traded in Other Exchanges
Address
20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.

Enzon Pharmaceuticals (STU:EZ1) Headlines

No Headlines